Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Kullmer

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Deutsche Medizinische Wochenschrift (1946)|November 15, 2000
[Oncologic mistletoe therapy: physicians' use and estimation of efficiency]K Münstedt, A Entezami, U Kullmer
European Journal of Cancer (Oxford, England : 1990)|October 25, 2000
The attitudes of physicians and oncologists towards unconventional cancer therapies (UCT)K Münstedt, A Entezami, A Wartenberg, et al.
Geburtshilfe Und Frauenheilkunde|April 29, 2014
Male and Female Physicians in Hospital Gynaecology Departments - Analysis of the Impact of "Feminisation" from the Viewpoint of Medical DirectorsT Riepen, V Möbus, U Kullmer, et al.
Journal of Perinatal Medicine|January 13, 2001
Wishes and expectations of pregnant women and their partners concerning deliveryK Münstedt, R von Georgi, V Eichel, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 7, 1999
Self-concept, body image, and use of unconventional therapies in patients with gynaecological malignancies in the state of complete remission and recurrenceU Kullmer, K Stenger, W Milch, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Epicutaneous breast forms. A new system promises to improve body image after mastectomyK Münstedt, B Schüttler, W Milch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Deutsche Medizinische Wochenschrift (1946)|November 15, 2000
[Oncologic mistletoe therapy: physicians' use and estimation of efficiency]K Münstedt, A Entezami, U Kullmer
European Journal of Cancer (Oxford, England : 1990)|October 25, 2000
The attitudes of physicians and oncologists towards unconventional cancer therapies (UCT)K Münstedt, A Entezami, A Wartenberg, et al.
Geburtshilfe Und Frauenheilkunde|April 29, 2014
Male and Female Physicians in Hospital Gynaecology Departments - Analysis of the Impact of "Feminisation" from the Viewpoint of Medical DirectorsT Riepen, V Möbus, U Kullmer, et al.
Journal of Perinatal Medicine|January 13, 2001
Wishes and expectations of pregnant women and their partners concerning deliveryK Münstedt, R von Georgi, V Eichel, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 7, 1999
Self-concept, body image, and use of unconventional therapies in patients with gynaecological malignancies in the state of complete remission and recurrenceU Kullmer, K Stenger, W Milch, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Epicutaneous breast forms. A new system promises to improve body image after mastectomyK Münstedt, B Schüttler, W Milch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 1